author-photo

Cedrick Wallet

French Institute of Health and Medical Research

10

Papers

129

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.

2020 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (13)
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.

2020 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (37)
Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.

2020 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (3)
Determinants of blood telomere length in antiretroviral treatment‐naïve HIV ‐positive participants enrolled in the NEAT 001/ ANRS 143 clinical trial

2019 Hiv Medicine
Show All
- Source
- Cite
- Save
Citations (4)
Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

2015 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (56)
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

2014 Lancet Neurology
Show All
- Source
- Cite
- Save
Citations (0)